Table 2.
Outcomes of patients with hypophosphatemia, normophosphatemia and hyperphosphatemia
| Variable | Hypophosphatemia group N = 188 |
Normophosphatemia group N = 865 |
Hyperphosphatemia group N = 369 |
p-value |
|---|---|---|---|---|
| Categorical outcomes | ||||
| ICU mortality, n (%) | 21 (11.4) | 143 (17.1) | 114 (32.0) | < 0.0001 |
| Hospital mortality, n (%) | 44 (23.5) | 226 (26.2) | 165 (44.7) | < 0.0001 |
| Continuous outcomes in all patients | ||||
| ICU length of stay (days), median (Q1, Q3) | 3.1 (0.83, 9.3) | 3.9 (1.04, 10.04) | 2.8 (0.7, 10) | 0.09 |
| Hospital length of stay (days), median (Q1, Q3) | 22 (7, 51) | 22 (12, 51) | 17 (7, 39) | 0.001 |
| Mechanical ventilation duration (days), median (Q1, Q3) | 0 (0, 4) | 1 (0, 6) | 2 (0, 6) | 0.005 |
| Continuous outcomes in survivors | ||||
| ICU length of stay (days), median (Q1, Q3) | 2.8 (0.7, 8.5) | 3.3 (0.9, 9.1) | 2.7 (0.4, 9.9) | 0.42 |
| Hospital length of stay (days), median (Q1, Q3) | 22 (10, 53) | 22 (12, 52) | 26.5 (14.5, 65) | 0.46 |
| Mechanical ventilation duration (days), median (Q1, Q3) | 0 (0, 4) | 0 (0, 3) | 1 (0, 4) | 0.21 |
ICU intensive care unit, Q1 the first quartile, Q3 the third quartile